Indi(R) Secures Contracts for Xpresys(R) Lung With Multiplan and Five Other PPOs; Blood Test for Pulmonary Nodules Now Available to 200 Million Covered Lives

SEATTLE, WA -- (Marketwired) -- 11/05/14 -- , an emerging leader in molecular diagnostics, today announced…

Continue Reading

Indi Molecular Expands Seed Round to $1.8 Million With Additional $300K From Asset Management Ventures

Company Publishes Three New Papers in Collaboration With Caltech to Further the Development of Synthetic Replacement…

Continue Reading

Indi(R) Announces Availability of Xpresys(TM) Lung Blood Test With Potential to Help Physicians Identify More Lung Nodules as Likely Benign and More Patients as Possible Candidates for Active Surveillance Instead of Invasive Procedures

Using Innovative Strategy, Test Does NOT Seek to Identify Lung Cancer; It Is ONLY Intended to…

Continue Reading

Indi Molecular Launches With $1.5 Million Seed Round Led by Interwest Partners

Pre-Eminent Team Backs Potential Replacement for Antibodies; Spinout From Integrated Diagnostics Will Further Develop New Binding…

Continue Reading

Integrated Diagnostics(R) Appoints CFO & VP Sales Prior to Launch of Lung Cancer Diagnostic

John Bencich Appointed Chief Financial Officer; Jill Tonachio Is Vice President for Sales

Continue Reading

Integrated Diagnostics(R) Secures $10 Million Third Tranche of Series A Financing

Company Appoints CFO and CBO, Completing Executive Team

Continue Reading